Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500081 | 0.94 | TSHR (0.37) | ACHETSHRCYP4F2CYP4A11LMNA | |
| SCHEMBL14715673 | 0.87 | TSHR (0.42) | TSHRLMNANAAAALDH1A1 | |
| SCHEMBL871598 | 0.85 | TSHR (0.40) | ACHETSHRCYP4F2CYP4A11LMNA | |
| SCHEMBL3912886 | 0.84 | ACHE (0.39) | ACHECYP4F2CYP4A11NAAAGAA | |
| SCHEMBL10087932 | 0.83 | LMNA (0.52) | TSHRLMNANAAAALDH1A1 | |
| SCHEMBL13133071 | 0.82 | TSHR (0.46) | TSHRCYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL19786567 | 0.82 | LMNA (0.37) | ACHETSHRLMNANAAAALDH1A1 | |
| SCHEMBL9110412 | 0.82 | TSHR (0.34) | TSHRLMNANAAAALDH1A1 | |
| SCHEMBL6897000 | 0.82 | LMNA (0.55) | ACHETSHRLMNANAAAALDH1A1 | |
| SCHEMBL452059 | 0.81 | ALDH1A1 (0.52) | ACHETSHRLMNANAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-3353145-B1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2022-09-28 | — | — | EP | disclosed |
| CN-113061089-A | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| CN-108283000-B | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2021-03-09 | — | — | US | disclosed |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2021-03-09 | — | — | US | disclosed |
| US-20200369599-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-11-26 | — | — | US | disclosed |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2019-10-29 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| EP-3353145-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW Laboratories Inc. (KY) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017049470-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (CN) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017049470-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (CN) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017050259-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017050259-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB2, GABRB3, GABRB1 | ACHE 551/4885TSHR 2992/4885CYP4F2 356/4885 |
| US-20200369599-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | ACHE 551/4885TSHR 2992/4885CYP4F2 356/4885 |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | ACHE 493/4885TSHR 3228/4885CYP4F2 515/4885 |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | ACHE 493/4885TSHR 3228/4885CYP4F2 515/4885 |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | ACHE 551/4885TSHR 2992/4885CYP4F2 356/4885 |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | ACHE 493/4885TSHR 3228/4885CYP4F2 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.